Avalyn Pharma IPO: offering terms from its S-1
Avalyn Pharma priced its IPO at $18 a share on 30 Apr 2026 and raised $300 million. Its shares trade on Nasdaq as AVLN.
Headlines
- Net loss, 2025
- $85M
- IPO price
- $18
- $300M raised
Avalyn Pharma IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- AVLN
- IPO price
- $18
- Shares offered
- 16,666,667
- Raised
- $300M
- Registered
- $345M, the amount the filing fee is paid on
- Underwriters
- Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities
- First filed
- 8 Apr 2026
Avalyn Pharma revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$91M | -$85M |
Avalyn Pharma share structure and company facts
- Share classes and votes
- Voting common stock: 1 vote per share, Non-voting common stock: 0 votes per share
- Employees
- 51
- Headquarters
- Boston, Massachusetts
Avalyn Pharma shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 30 Apr 2026
- First close
- $29.49
- +64% on the IPO price
- Latest close
- $27.14
- +51% on the IPO price
Avalyn Pharma's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Avalyn Pharma's newest prospectus (424B4 filed 30 Apr 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.